Christopher W Farnsworth1, James B Case2, Karl Hock1, Rita E Chen1,2, Jane A O'Halloran2, Rachel Presti2, Charles W Goss3, Adriana M Rauseo2, Ali Ellebedy1, Elitza S Theel4, Michael S Diamond1,2,5, Jeffrey P Henderson2,5. 1. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. 2. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. 3. Division of Biostatistics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA. 4. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 5. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
Abstract
BACKGROUND: The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic convalescent plasma (CCP) in over a century. Initial identification of high titer units was based on dose-response data using the Ortho VITROS IgG assay. The proliferation of severe acute respiratory syndrome coronavirus 2 serological assays and non-uniform application has led to uncertainty about their interrelationships. The purpose of this study was to establish correlations and analogous cutoffs between multiple serological assays. METHODS: We compared the Ortho, Abbott, Roche, an anti-spike (S) ELISA, and a virus neutralization assay. Relationships relative to FDA-approved cutoffs under the CCP emergency use authorization were identified in convalescent plasma from a cohort of 79 donors from April 2020. RESULTS: Relative to the neutralization assay, the spearman r value of the Ortho Clinical, Abbott, Roche, anti-S ELISA assays was 0.65, 0.59, 0.45, and 0.76, respectively. The best correlative index for establishing high-titer units was 3.87 signal-to-cutoff (S/C) for the Abbott, 13.82 cutoff index for the Roche, 1:1412 for the anti-S ELISA, 1:219 by the neutralization assay, and 15.9 S/C by the Ortho Clinical assay. The overall agreement using derived cutoffs compared to a neutralizing titer of 1:250 was 78.5% for Abbott, 74.7% for Roche, 83.5% for the anti-S ELISA, and 78.5% for Ortho Clinical. DISCUSSION: Assays based on antibodies against the nucleoprotein were positively associated with neutralizing titers and the Ortho assay, although their ability to distinguish FDA high-titer specimens was imperfect. The resulting relationships help reconcile results from the large body of serological data generated during the COVID-19 pandemic.
BACKGROUND: The COVID-19 pandemic has been accompanied by the largest mobilization of therapeutic convalescent plasma (CCP) in over a century. Initial identification of high titer units was based on dose-response data using the Ortho VITROS IgG assay. The proliferation of severe acute respiratory syndrome coronavirus 2 serological assays and non-uniform application has led to uncertainty about their interrelationships. The purpose of this study was to establish correlations and analogous cutoffs between multiple serological assays. METHODS: We compared the Ortho, Abbott, Roche, an anti-spike (S) ELISA, and a virus neutralization assay. Relationships relative to FDA-approved cutoffs under the CCP emergency use authorization were identified in convalescent plasma from a cohort of 79 donors from April 2020. RESULTS: Relative to the neutralization assay, the spearman r value of the Ortho Clinical, Abbott, Roche, anti-S ELISA assays was 0.65, 0.59, 0.45, and 0.76, respectively. The best correlative index for establishing high-titer units was 3.87 signal-to-cutoff (S/C) for the Abbott, 13.82 cutoff index for the Roche, 1:1412 for the anti-S ELISA, 1:219 by the neutralization assay, and 15.9 S/C by the Ortho Clinical assay. The overall agreement using derived cutoffs compared to a neutralizing titer of 1:250 was 78.5% for Abbott, 74.7% for Roche, 83.5% for the anti-S ELISA, and 78.5% for Ortho Clinical. DISCUSSION: Assays based on antibodies against the nucleoprotein were positively associated with neutralizing titers and the Ortho assay, although their ability to distinguish FDA high-titer specimens was imperfect. The resulting relationships help reconcile results from the large body of serological data generated during the COVID-19 pandemic.
Authors: Artur Belov; Yin Huang; Carlos H Villa; Barbee I Whitaker; Richard Forshee; Steven A Anderson; Anne Eder; Nicole Verdun; Michael J Joyner; Scott R Wright; Rickey E Carter; Deborah T Hung; Mary Homer; Corey Hoffman; Michael Lauer; Peter Marks Journal: Am J Hematol Date: 2022-03-24 Impact factor: 13.265
Authors: Catherine L Omosule; Justin Conklin; Sohkna Seck; Renée Howell; Karl G Hock; Claire Ballman; James Freeman; Leon Du Toit; Erik Dubberke; Christopher W Farnsworth Journal: Clin Biochem Date: 2022-01-03 Impact factor: 3.281
Authors: Nicholas E Larkey; Radwa Ewaisha; Michael A Lasho; Matthew M Roforth; Dane Granger; Calvin R Jerde; Liang Wu; Amy Gorsh; Stephen A Klassen; Jonathon W Senefeld; Michael J Joyner; Nikola A Baumann; Elitza S Theel; John R Mills Journal: Microbiol Spectr Date: 2022-07-05